The improved killing efficacy of the same radioactivity when delivered by combinations of the two carriers was also observed in vitro on multicellular spheroids—used as surrogates of tumors' avascular regions—that were formed by prostate cancer cells with varying levels of PSMA expression. This evidence concerns the gene FOLH1 and prostate cancer.